Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2023-10-17 00:00:00 ET · period of report 2023-10-17 · accession 0001415889-23-014366 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-17 | 2023-10-17 | HALO | LaBarre Michael J. | SVP, Chief TECHNICAL Off | M - OptEx | $19.98 | +10.0K | 161.9K | +7% | +$199.8K |
| D | 2023-10-17 | 2023-10-17 | HALO | LaBarre Michael J. | SVP, Chief TECHNICAL Off | S - Sale+OE | $36.52 | -10.0K | 151.9K | -6% | -$365.2K |
| D | 2023-10-17 | 2023-10-17 | HALO | LaBarre Michael J. | SVP, Chief TECHNICAL Off | M - OptEx | $0.00 | -10.0K | 41.1K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-17 | M | A | 10,000 | $19.98 | 161,911 | D | — | — | |
| 2 | Common | Common Stock | 2023-10-17 | S | D | 10,000 | $36.52 | 151,911 | D | — | — | |
| 3 | Derivative | Option to Purchase Common Stock | 2023-10-17 | M | D | 10,000 | $0.00 | 41,099 | D | $19.98 · — to 2030-02-10 | 10,000 Common Stock | (F2) This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. |